Ipratropium
This anticholinergic bronchodilator is used to relieve bronchospasm in COPD and asthma by blocking muscarinic receptors in the airways, preventing the smooth muscle constriction caused by the vagal nerve. It helps open the airways and reduce mucus secretion. It is available in inhaled forms for maintenance therapy and is often combined with short-acting beta-agonists.
Molekularmasse
332,5000 g/mol
LogP
2,60
TPSA
46,50 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CC(C)[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2
InChI
InChI=1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1/t16-,17+,18+,19?,21?
Molecular Formula
C20H30NO3+
HBD / HBA
1 / 3
Rotierbare Bindungen
6
Schwere Atome
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
This anticholinergic bronchodilator is used to relieve bronchospasm in COPD and asthma by blocking muscarinic receptors in the airways, preventing the smooth muscle constriction caused by the vagal nerve. It helps open the airways and reduce mucus secretion. It is available in inhaled forms for maintenance therapy and is often combined with short-acting beta-agonists.
Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.
Yes, Ipratropium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1621597. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 657309. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ipratropium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ipratropium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ipratropium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ipratropium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ipratropium"></drugfyi-drug>